CJC-1295/Ipamorelin: The Complete Guide to the Growth Hormone Peptide Stack
After age 30, your body produces roughly 15% less growth hormone every decade. This peptide stack doesn't replace what you've lost with synthetic hormones. It tells your body to start making more of its own again. One peptide provides the sustained signal. The other amplifies each pulse. Together, they're the most popular growth hormone optimization protocol in peptide therapy.
In this article
Key Takeaways
- CJC-1295/Ipamorelin combines two peptides that work synergistically to boost natural growth hormone production.
- CJC-1295 (with DAC) extends GH release duration while Ipamorelin triggers clean, selective GH pulses without cortisol or prolactin spikes.
- Benefits include improved body composition, deeper sleep, faster recovery, and enhanced skin quality.
- Neither peptide is FDA-approved. They are compounded together and prescribed via telehealth at PeRx.
- Subcutaneous injection before bed. Most patients notice sleep and recovery improvements within 2-4 weeks.
Quick Facts
Category
Growth hormone secretagogues
How It Works
Stimulates natural GH production
CJC-1295 Type
GHRH analog (30 amino acids)
Ipamorelin Type
Selective GH secretagogue (5 amino acids)
Primary Uses
Sleep, body composition, recovery, anti-aging
First Benefit Noticed
Improved deep sleep (weeks 1-2)
The Origin Story
The CJC-1295/Ipamorelin stack is actually the convergence of two completely separate research paths spanning decades, two continents, and a Nobel Prize. Understanding where these molecules came from explains why they work so well together.
Path One: From a Nobel Prize to CJC-1295
In the late 1960s, a French-American physiologist named Roger Guillemin was working at the Salk Institute in La Jolla, California, trying to prove something most of the scientific establishment thought was impossible: that the brain's hypothalamus produces specific hormones that control the pituitary gland. The skepticism was fierce. Funding was scarce. The work required processing hundreds of thousands of sheep hypothalami just to extract enough material to analyze.
Guillemin proved them all wrong. His team identified TRH (which controls thyroid function) in 1969, then GnRH (which controls reproductive hormones) in 1972. He won the Nobel Prize in Physiology or Medicine in 1977 for this work. But there was still one big prize left: the hormone that controls growth hormone release from the pituitary. Guillemin had found somatostatin (which inhibits GH release) in 1973, but the stimulating factor kept eluding him.
The breakthrough came from an unexpected source. Rather than trying to extract the hormone from brain tissue (which contained vanishingly small amounts), Guillemin's team obtained tissue from a rare pancreatic tumor in France that was producing the mystery hormone in large quantities. In November 1982, they published the structure of growth hormone-releasing hormone (GHRH) in Science. The same week, Wylie Vale's group at the Salk Institute independently published the same structure in Nature. After 40 years of searching, the final piece of the hypothalamic puzzle was in place.
That discovery set off a cascade of pharmaceutical development. The first 29 amino acids of GHRH turned out to be the active region. Scientists synthesized this fragment as the drug Sermorelin, which the FDA approved in 1997 for treating growth hormone deficiency in children. Sermorelin worked, but it had a problem: it degraded rapidly in the body, with a half-life of only about 10-12 minutes.
In the mid-2000s, a Canadian biotech company called ConjuChem Biotechnologies set out to fix that problem. They modified the 29-amino-acid GHRH fragment at four key positions (making it more resistant to enzymatic breakdown) and added their proprietary Drug Affinity Complex (DAC) technology, which allowed the peptide to bind to albumin in the blood. The result was CJC-1295: a GHRH analog with a half-life of 6-8 days instead of minutes. A single injection could sustain elevated growth hormone levels for nearly a week.
Guillemin R et al., "Growth hormone-releasing factor from a human pancreatic tumor," Science, 1982. Teichman SL et al., "Prolonged stimulation of GH and IGF-I by CJC-1295," J Clin Endocrinol Metab, 2006. View study
Path Two: The search for a clean growth hormone trigger
While one line of research was perfecting the GHRH signal, an entirely separate team at Novo Nordisk in Denmark was working on a different problem. By the mid-1990s, scientists had discovered that the body has a second system for triggering growth hormone release: the ghrelin pathway. Small synthetic peptides called growth hormone-releasing peptides (GHRPs) could mimic ghrelin and trigger a quick burst of GH from the pituitary.
The problem was that existing GHRPs were messy. GHRP-6 worked, but it also spiked cortisol (the stress hormone) and dramatically increased appetite. GHRP-2 was similarly non-selective. If you wanted to boost growth hormone, you had to accept the side effects of elevated stress hormones and constant hunger. For therapeutic use, this was a dealbreaker.
The Novo Nordisk team, led by researchers including K. Raun and M. Ankersen, embarked on what they described as a "major chemistry programme" to find something better. They systematically stripped down the GHRP-1 molecule, removing the central dipeptide and testing variations until they found a five-amino-acid sequence that released growth hormone with the same potency as GHRP-6, but without touching cortisol, prolactin, ACTH, or appetite. They tested it at doses 200 times higher than the effective GH-releasing dose. Still no cortisol spike. Still no appetite increase.
They published their findings in the European Journal of Endocrinology in 1998 with a title that captured the significance: "Ipamorelin, the first selective growth hormone secretagogue." It was a quiet revolution. For the first time, clinicians had a way to trigger immediate GH pulses without the hormonal collateral damage that came with every other option.
Raun K et al., "Ipamorelin, the first selective growth hormone secretagogue," European Journal of Endocrinology, 1998. View study
1977
Nobel Prize for hypothalamic hormones
Roger Guillemin wins the Nobel Prize for proving the hypothalamus produces hormones controlling the pituitary. The growth hormone-releasing factor remains elusive.
1982
GHRH structure published
Guillemin's team isolates GHRH from a rare pancreatic tumor. The same week, Wylie Vale's group independently publishes the same structure.
1997
First GHRH drug reaches market
Scientists synthesize the active 29-amino-acid fragment of GHRH as a drug. It works, but degrades in the body within minutes (half-life of 10-12 min). A longer-lasting version is needed.
2006
CJC-1295 solves the half-life problem
ConjuChem modifies 4 amino acids to resist enzymatic breakdown. Phase I trial shows 2-10x GH increases lasting up to 6 days from a single injection.
1980s
Ghrelin pathway discovered
Scientists find a second system for triggering GH release: the ghrelin receptor on the pituitary. Small peptides (GHRPs) can mimic this signal.
1990s
GHRPs work but have side effects
GHRP-6 and GHRP-2 trigger GH release but also spike cortisol, prolactin, and appetite. For therapeutic use, this is a dealbreaker.
1998
Ipamorelin: first selective GH secretagogue
Novo Nordisk publishes a 5-amino-acid peptide that matches GHRP-6 potency with zero cortisol or appetite increase, even at 200x the effective dose.
2010s
The CJC-1295/Ipamorelin Stack Emerges
Compounding pharmacies combine the no-DAC version of CJC-1295 with Ipamorelin. Two receptor pathways, one sustained signal and one pulse amplifier, producing 3-5x more GH than either alone.
Why They're Better Together
Think of CJC-1295 and Ipamorelin as relay partners. CJC-1295 is the long-distance runner: it sustains an elevated baseline of growth hormone signaling for days after each injection. Ipamorelin is the sprinter: it triggers an immediate, powerful GH pulse from the pituitary. One provides duration, the other provides intensity. Together, they produce 3-5 times more growth hormone release than either peptide alone, while preserving the natural pulsatile pattern your body prefers.
How the Stack Actually Works
To understand why CJC-1295/Ipamorelin is so effective, you need a quick tour of how your body manages growth hormone. It's not as complicated as it sounds, and understanding the system makes the entire protocol click into place.
Your pituitary gland and the two-signal system
Your pituitary gland (a pea-sized structure at the base of your brain) is the factory that produces growth hormone. But it doesn't just churn it out continuously. It releases GH in pulses, mainly during deep sleep and after exercise. Two competing signals control this pulsing: GHRH tells the pituitary to release GH, and somatostatin tells it to stop. The balance between these two signals creates the natural rhythm of GH pulses throughout the day.
There's also a third player: ghrelin (produced primarily in the stomach) acts on its own receptor on the pituitary to amplify GH release. Think of GHRH as the gas pedal, somatostatin as the brake, and ghrelin as the turbo boost.
As you age, this system gradually weakens. GHRH production declines. Somatostatin activity increases. The pulses get smaller and less frequent. By age 60, most people are producing a fraction of the growth hormone they made at 25.
What CJC-1295 does: sustained GHRH signaling
CJC-1295 (without DAC, also called Modified GRF 1-29) is a modified version of the first 29 amino acids of GHRH. It binds to the same GHRH receptors on the pituitary, telling somatotroph cells to produce and release more growth hormone. The four amino acid substitutions (at positions 2, 8, 15, and 27) make it resistant to the enzymes that would rapidly destroy natural GHRH. The result is a sustained GHRH signal that keeps the pituitary primed for GH release over an extended period.
The 2006 human trial by Teichman et al. found that CJC-1295 produced dose-dependent increases in mean plasma GH concentrations of 2 to 10-fold and IGF-1 increases of 1.5 to 3-fold, with effects lasting up to 6 days from a single injection. After multiple doses, IGF-1 levels remained elevated for up to 28 days.
What Ipamorelin does: selective GH pulse amplification
Ipamorelin is a five-amino-acid peptide that mimics ghrelin's action at the growth hormone secretagogue receptor (GHS-R) on the pituitary. It triggers an immediate, potent burst of GH release. But here's what makes it special: unlike ghrelin itself (which increases appetite) and unlike older GHRPs (which spike cortisol and prolactin), ipamorelin is selective. It releases growth hormone and essentially nothing else.
The 1998 Raun et al. study demonstrated this selectivity dramatically. In swine, ipamorelin released GH with potency comparable to GHRP-6. But when they measured cortisol and ACTH levels, ipamorelin showed no increase, even at doses more than 200 times higher than the effective GH-releasing dose. GHRP-6 and GHRP-2, by contrast, significantly elevated both stress hormones at normal doses.
This selectivity is why Ipamorelin is the preferred partner for CJC-1295. You get the GH amplification without the appetite spike, without the cortisol elevation, and without the prolactin increase that plagues other secretagogues.
The synergy: why 1 + 1 = 3
CJC-1295 and Ipamorelin work on different receptor systems on the pituitary gland. CJC-1295 activates the GHRH receptor. Ipamorelin activates the ghrelin receptor. Because they're hitting two separate pathways simultaneously, the combined effect is greater than the sum of the parts. Studies suggest the combination produces a 3-5 fold increase in growth hormone release compared to either peptide used alone.
And because both peptides stimulate your body's own GH production (rather than injecting synthetic growth hormone), the pulsatile release pattern is preserved. Your pituitary still produces GH in the natural wave pattern your body was designed for, just with bigger waves and higher peaks. This is fundamentally different from exogenous HGH, which creates a flat, constant elevation that can suppress your body's own production over time.
How CJC-1295/Ipamorelin Works
Four mechanisms that make CJC-1295/Ipamorelin unique among healing peptides
Sustained GHRH Signaling (CJC-1295)
Binds GHRH receptors on the pituitary, keeping somatotroph cells primed for GH release. Four amino acid substitutions resist enzymatic breakdown, extending the signal for hours instead of minutes.
Selective GH Pulse (Ipamorelin)
Activates the ghrelin receptor (GHS-R) on the pituitary to trigger an immediate GH burst. Unlike GHRP-6, it does not increase cortisol, prolactin, or appetite, even at 200x the effective dose.
Synergistic Amplification
Two receptor systems activated simultaneously produce 3-5x more GH than either peptide alone. The combined effect preserves the natural pulsatile pattern your body prefers, just with bigger waves.
Negative Feedback Preserved
Unlike exogenous HGH (which suppresses your own production), this stack works with your pituitary. Somatostatin still applies the brake when needed, preventing runaway GH elevation.
CJC-1295/Ipamorelin is the synthetic version of thymosin beta-4, one of the most abundant peptides in the human body.
DAC vs. No DAC: Which CJC-1295 Are You Getting?
This is a common source of confusion. CJC-1295 with DAC (Drug Affinity Complex) binds to albumin in the blood, giving it a half-life of 6-8 days and requiring only weekly injections. CJC-1295 without DAC (also called Modified GRF 1-29 or Mod GRF) has a half-life of about 30 minutes and requires daily dosing. Despite the confusing names, they are functionally different molecules.
When paired with Ipamorelin, the no-DAC version is almost always used. The shorter half-life preserves the natural pulsatile GH pattern rather than creating constant elevation. This is considered physiologically preferable and reduces the risk of pituitary desensitization. When you see "CJC-1295/Ipamorelin" from a compounding pharmacy or provider, it's typically the no-DAC version.
What CJC-1295/Ipamorelin Can Do For You
Unlike the healing peptides (BPC-157, TB-500), CJC-1295/Ipamorelin isn't targeting a specific injury. It's optimizing a system. By restoring growth hormone levels closer to where they were in your mid-twenties, the effects ripple across nearly every aspect of physical performance, body composition, and recovery. Here's what the research and clinical experience show.
Deep, restorative sleep
This is the first benefit most people notice, often within the first week. It's also the most reliably reported. There's a reason it works so quickly: growth hormone-releasing hormone is directly involved in sleep architecture. Research going back to the 1990s has shown that GHRH activity decreases wakefulness and increases slow-wave sleep, the deepest and most physically restorative stage. CJC-1295, as a GHRH analog, enhances this pathway directly.
Users consistently report falling asleep faster, sleeping more deeply, waking up less during the night (the infamous 3 AM wake-up many people experience tends to resolve), and feeling genuinely rested in the morning. This isn't a sedative effect. It's your brain spending more time in the deep sleep phases where physical recovery, memory consolidation, and hormone production naturally occur.
The timing of the injection matters here. Taking CJC-1295/Ipamorelin before bed aligns the peptide-driven GH pulse with your body's natural nighttime production peak, amplifying rather than overriding your circadian rhythm.
Steiger A et al., "Effects of GHRH on sleep EEG," Neuroendocrinology, 1992. Obal F & Krueger JM, "GHRH and sleep," Sleep Medicine Reviews, 2004.
Body composition: fat loss and lean muscle
Elevated growth hormone drives your body to prioritize fat as an energy source while preserving and building lean muscle tissue. This is the combination that makes CJC-1295/Ipamorelin popular for body composition improvement. Growth hormone stimulates lipolysis (fat breakdown) in adipose cells while promoting protein synthesis in muscle tissue. The result is a gradual but steady shift in the ratio of fat to lean mass.
Clinical experience suggests most patients lose 10-20+ pounds of fat over 4-6 months while gaining 3-8 pounds of lean muscle, though individual results vary significantly based on diet, training, and starting point. Active people benefit more from the stack than sedentary people. The peptides amplify what your lifestyle is already doing. They don't replace it.
Recovery and repair
Growth hormone is central to tissue repair. By elevating GH and downstream IGF-1 levels, CJC-1295/Ipamorelin accelerates recovery from exercise, reduces muscle soreness, and supports faster healing of minor injuries. Increased collagen production supports joint health, tendon integrity, and connective tissue resilience. Athletes on this protocol commonly report being able to train harder, more frequently, and with less downtime between sessions.
Skin, hair, and anti-aging effects
Growth hormone stimulates collagen production and cellular regeneration throughout the body, including the skin. Over 3-6 months, many users report improved skin elasticity, reduced fine lines, better skin hydration, and improved hair quality. These changes tend to be gradual and cumulative rather than dramatic, but they're consistently reported. The mechanism is straightforward: more GH means more collagen synthesis, more cellular turnover, and better tissue quality across the board.
Energy and cognitive clarity
Better sleep alone would improve energy and mental sharpness. But elevated growth hormone independently supports metabolic efficiency, glucose utilization, and neuronal health. Users report more sustained energy throughout the day (not a stimulant-like spike), improved focus and mental clarity, and reduced afternoon crashes. This tends to build over the first several weeks as sleep quality improves and the downstream effects of GH optimization accumulate.
What You Should Know Before Starting
Growth hormone optimization is not the fountain of youth
GH levels do decline with age, and restoring them has measurable benefits for sleep, body composition, and recovery. But the broader "anti-aging" claims that surround growth hormone therapy often outrun the evidence. There's no strong evidence that increasing GH via secretagogues can reverse aging itself. What it can do is optimize specific physiological functions that tend to deteriorate as GH declines. Set your expectations around those specific, measurable outcomes rather than a general promise of turning back the clock.
IGF-1 monitoring is important
When you increase growth hormone production, your liver responds by producing more IGF-1 (insulin-like growth factor 1). IGF-1 mediates many of GH's beneficial effects, but chronically elevated IGF-1 has been associated with increased cancer risk in epidemiological studies. This doesn't mean CJC-1295/Ipamorelin causes cancer. But it does mean periodic IGF-1 testing through your primary care physician or an independent lab is worth doing during any GH peptide protocol. The goal is optimization within a healthy range, not maximal elevation.
The CJC-1295 DAC clinical trial context
Transparency matters. During a Phase II clinical trial of CJC-1295 with DAC for HIV-related lipodystrophy in 2006, a trial participant in Argentina died after receiving their eleventh injection. ConjuChem halted the study. The attending physician's assessment was that the most likely explanation was pre-existing coronary artery disease with plaque rupture, unrelated to the study drug. The Phase I trial that preceded it found the drug safe and well-tolerated. The no-DAC version commonly used today was not the subject of this trial. This context is important, and any provider dismissing it rather than discussing it openly should raise a red flag.
Lifestyle multiplies results
CJC-1295/Ipamorelin amplifies what you're already doing. If you're training regularly, eating well, and prioritizing sleep, the peptides dramatically enhance your results. If you're sedentary with a poor diet, the benefits will be modest at best. Clinicians consistently report that active people see significantly better outcomes than inactive people on the same protocol. This isn't a replacement for lifestyle fundamentals. It's a multiplier.
Your Results Timeline
CJC-1295/Ipamorelin works with your body's natural systems, which means results are gradual and cumulative rather than overnight. Here's the realistic progression most people experience.
Week 1-2
Sleep Transforms First
This is the most consistent early change. Deeper sleep, less nighttime waking, and waking up feeling actually rested. Many people notice this within the first few days. Energy levels begin to stabilize. Recovery from workouts starts improving. You may notice mild water retention as GH levels adjust.
Week 2-4
Energy and Recovery Improve
Sustained energy throughout the day replaces afternoon crashes. Workout recovery shortens noticeably. You can train harder with less soreness the next day. Mental clarity improves. Some people notice early improvements in skin quality. The compounding effect of better sleep starts showing in every other area.
Week 4-8
Body Composition Shifts Begin
Subtle but measurable changes in body composition start. Clothes fit differently. Stubborn fat areas begin responding. Muscle tone improves, especially if you're training with resistance. Skin starts looking better. Recovery is now noticeably faster than baseline. You're sleeping more deeply and consistently than you have in years.
Month 2-3
Visible Changes
Body composition changes become visible. Fat loss is noticeable, especially around the midsection. Lean muscle definition improves. Skin elasticity and quality continue improving. Hair may appear thicker. People start commenting on how you look. The cumulative effect of months of optimized GH, better sleep, and improved recovery produces a meaningful transformation.
Month 4-6
Full Optimization
Maximum benefits are typically achieved in this window. Significant body composition change. Strong, consistent sleep. High energy. Fast recovery. Improved skin quality. Some people continue beyond 6 months with monitoring; others cycle off and reassess. A 4-week break after 12-16 weeks of use allows IGF-1 levels to stabilize before a potential second cycle.
Safe Use, Sourcing, and Protocols
Growth hormone peptides require even more attention to sourcing than healing peptides like BPC-157 and TB-500. You're directly influencing your endocrine system, and what's in the vial matters enormously.
Why sourcing is critical for GH peptides
With CJC-1295/Ipamorelin, you need to know two things about your product: that it actually contains the correct peptides at the stated concentrations, and that it's the right version of CJC-1295 (with or without DAC). The "research chemical" market is flooded with products that are underdosed, mislabeled, degraded, or contaminated. When you're injecting something that directly affects hormone production, quality isn't optional.
PeRx connects you with a licensed provider for pharmaceutical-grade CJC-1295/Ipamorelin from licensed compounding pharmacies. Proper certificates of analysis, verified amino acid sequencing, and correct peptide identification. No grey market guesswork.
Typical protocols
PeRx ships CJC-1295/Ipamorelin as a combined formulation, fully reconstituted and ready to use. The protocol is straightforward compared to healing peptides: one injection per day, same time, same dose.
Typical CJC-1295/Ipamorelin Protocol
Dose
Per provider protocol
Frequency
Once daily, 5 days on / 2 days off
Timing
Before bed, 1-2 hours after last meal
Administration
Subcutaneous injection (abdomen)
Cycle Length
12-16 weeks, then 4-week break
Lab Monitoring
Ask your PCP to check IGF-1 at baseline and periodically
The evening, fasted timing is important. Growth hormone production naturally peaks during deep sleep, and food intake (particularly carbohydrates and fats) can blunt the GH response. Injecting 1-2 hours after your last meal, shortly before bed, aligns the peptide-driven GH pulse with your body's natural nighttime peak and maximizes the sleep-promoting effects of GHRH signaling.
The 5 days on, 2 days off schedule prevents pituitary receptor desensitization. Your body adapts to constant stimulation by downregulating receptors. The two rest days keep the receptors responsive. The 4-week break after each 12-16 week cycle serves the same purpose on a longer timeline and allows IGF-1 levels to normalize.
Your prescribing provider will determine the appropriate dose based on your labs, health history, and treatment goals. If you can, ask your primary care physician to check baseline IGF-1 and metabolic markers before starting, and periodically during use.
CJC-1295/Ipamorelin vs. the Alternatives
There are several ways to address declining growth hormone levels. CJC-1295/Ipamorelin sits in a specific spot on the spectrum: more effective than first-generation options, safer and more affordable than exogenous HGH, and more selective than oral secretagogues. Here's how it compares.
| CJC-1295/Ipamorelin | HGH (Synthetic) | Sermorelin | |
|---|---|---|---|
| How It Works | Stimulates natural GH production via two pathways | Directly injects synthetic growth hormone | Stimulates GH via GHRH pathway only |
| GH Pattern | Preserves natural pulsatile release | Flat, constant elevation | Preserves pulsatile release |
| Selectivity | High. No cortisol/prolactin increase. | N/A (direct hormone) | Moderate |
| Effectiveness | 3-5x GH amplification vs single peptide | Highest absolute GH levels | Effective but shorter-acting (~3x less than CJC) |
| Side Effects | Mild (injection site, occasional flushing) | Joint pain, insulin resistance, edema, organ growth risk | Similar to CJC/Ipam but less potent |
| Administration | Daily SubQ injection, before bed | Daily SubQ injection | Daily SubQ injection |
| Cost | Moderate | Very high ($800-2,000+/mo) | Moderate |
| Best For | Overall GH optimization with safety | Severe GH deficiency, clinical use | Conservative first-line approach |
CJC-1295/Ipamorelin hits the sweet spot for most people. It's substantially more effective than Sermorelin (roughly 3x better GH secretion according to clinical data), significantly safer and more affordable than exogenous HGH, and preserves the natural pulsatile GH pattern that your body prefers. For growth hormone optimization without the risks and cost of synthetic HGH, it's the consensus first-choice protocol in modern peptide therapy.
Frequently Asked Questions
Ready to optimize your growth hormone?
Pharmaceutical-grade CJC-1295/Ipamorelin, delivered to your door with everything you need.
View CJC-1295/IpamorelinMedical Disclaimer
The information provided on this website, including all articles, guides, and educational content, is for informational and educational purposes only and is not intended as medical advice, diagnosis, or treatment. Nothing on this site should be construed as a substitute for professional medical advice from a qualified healthcare provider.
The majority of peptides discussed on this site are not approved by the U.S. Food and Drug Administration (FDA) for the indications described. They are classified as bulk drug substances and are available only through a licensed prescribing provider and compounding pharmacy. All treatments require a valid prescription and provider oversight.
The majority of published research on peptide therapies has been conducted in preclinical (animal) models. While early human data is encouraging, comprehensive clinical trial data remains limited for most peptide compounds. Individual results may vary significantly based on health status, injury type, and other factors. No specific outcomes are guaranteed.
Certain peptides discussed on this site are classified as prohibited substances by the World Anti-Doping Agency (WADA) and are banned by major sports organizations including the NFL, NCAA, UFC, NBA, MLB, NHL, and PGA. If you are subject to anti-doping testing, consult your governing body before considering any peptide therapy.
Statements on this website have not been evaluated by the Food and Drug Administration. Products and therapies discussed are not intended to diagnose, treat, cure, or prevent any disease.
© 2026 Wellness MD Group PC DBA PeRx. All rights reserved.
Ready to get started with CJC-1295/Ipamorelin?
Pharmaceutical-grade CJC-1295/Ipamorelin, prescribed by a licensed provider and shipped to your door.